
DBVT Stock Forecast & Price Target
DBVT Analyst Ratings
Bulls say
DBV Technologies is well positioned to become a leader in the immunotherapy space for peanut allergy with its novel Viaskin technology platform. The company has a strong pipeline, with its main product candidate, Viaskin Peanut, targeting a highly unmet need in the market. Despite some delays and setbacks, DBV has a solid financial position with enough runway into 2027, and their potential breakthrough designation may lead to a swift uptake of their product upon approval. However, there are risks and uncertainties related to clinical trials, regulatory approval, and competition in the market, as well as the potential need for additional financing. Overall, DBV is a strong investment opportunity with a positive outlook for the future.
Bears say
DBV Technologies is well-positioned for long-term success with their novel EPIT technology and strong pipeline of potential treatments for various food allergies. However, with BLA submissions not expected until 2026 and potential competition from other novel therapies, the company may face challenges in gaining market share and achieving high sales. Additionally, the company's current cash reserve may not be enough to sustain operations until the expected BLA submissions in 2026, leading to potential dilution for shareholders in the future. These factors contribute to a negative outlook on DBV Technologies's stock.
This aggregate rating is based on analysts' research of DBV Technologies SA Sponsored ADR and is not a guaranteed prediction by Public.com or investment advice.
DBVT Analyst Forecast & Price Prediction
Start investing in DBVT
Order type
Buy in
Order amount
Est. shares
0 shares